Latest filings (excl ownership)
6-K
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
22 Apr 24
6-K
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
9 Apr 24
40-F
2023 FY
Annual report (Canada)
7 Mar 24
6-K
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
6-K
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
4 Mar 24
6-K
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
27 Feb 24
6-K
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
15 Feb 24
6-K
Profound Medical Announces Non-Brokered Private Placement
16 Jan 24
6-K
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
3 Jan 24
6-K
Material Change Report
2 Jan 24
6-K
Titan Partners Group LLC, a division of American Capital Partners, LLC
28 Dec 23
SUPPL
Supplemental materials (foreign)
28 Dec 23
6-K
Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares
28 Dec 23
6-K
Profound Medical Announces Proposed Public Offering of Common Shares
27 Dec 23
SUPPL
Supplemental materials (foreign)
27 Dec 23
6-K
Profound Medical Announces Proposed Public Offering of Common Shares
27 Dec 23
6-K
Profound Medical to Participate in the Stifel 2023 Healthcare Conference
8 Nov 23
6-K
Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting
3 Nov 23
6-K
Profound Medical Announces Third Quarter 2023 Financial Results
2 Nov 23
6-K
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
19 Oct 23
6-K
Current report (foreign)
10 Oct 23
6-K
Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost
25 Sep 23
6-K
Current report (foreign)
21 Sep 23
6-K
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
19 Sep 23
6-K
Profound Medical Announces At-the-Market Offering of up to US$30,000,000
6 Sep 23
SUPPL
Supplemental materials (foreign)
6 Sep 23
6-K
Profound Medical Announces At-the-Market Offering of up to US$30,000,000
6 Sep 23
6-K
Profound Medical Announces Second Quarter 2023 Financial Results
9 Aug 23
6-K
Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow
2 Aug 23
6-K
Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases
2 Jun 23
6-K
Profound Medical Announces Upcoming Investor Events
30 May 23
6-K
Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference
18 May 23
6-K
Profound Medical Annual and Special Meeting of Shareholders Voting Results
17 May 23
6-K
Profound Medical Announces First Quarter 2023 Financial Results
10 May 23
6-K
TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting
1 May 23
6-K
Current report (foreign)
1 May 23
6-K
Current report (foreign)
25 Apr 23
6-K
Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow
19 Apr 23
6-K
Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference
19 Apr 23
40-F
2022 FY
Annual report (Canada)
7 Mar 23
Latest ownership filings
144
Notice of proposed sale of securities
26 Mar 24
SC 13G/A
DASEKE DON R
13 Mar 24
SC 13G/A
GAGNON SECURITIES LLC
13 Feb 24
SC 13G/A
LETKO, BROSSEAU & ASSOCIATES INC
12 Feb 24
SC 13G/A
FIL Ltd
9 Feb 24
SC 13G
DASEKE DON R
11 Jan 24
SC 13G/A
GAGNON SECURITIES LLC
13 Feb 23
SC 13G/A
Flynn James E
10 Feb 23
SC 13G
LETKO, BROSSEAU & ASSOCIATES INC
10 Feb 23
SC 13G/A
FIL Ltd
9 Feb 23
SC 13G/A
GAGNON SECURITIES LLC
6 Feb 23
SC 13G/A
GAGNON SECURITIES LLC
11 Oct 22
SC 13G/A
GAGNON SECURITIES LLC
10 Mar 22
SC 13G/A
Genesys Ventures II LP
14 Feb 22
SC 13G/A
Flynn James E
11 Feb 22
SC 13G/A
FIL Ltd
9 Feb 22
SC 13G/A
GAGNON SECURITIES LLC
3 Feb 22
SC 13G/A
GAGNON SECURITIES LLC
3 Feb 22
SC 13G/A
Genesys Ventures II LP
16 Feb 21
SC 13G/A
GAGNON SECURITIES LLC
9 Feb 21
SC 13G/A
FIL Ltd
8 Feb 21
SC 13G
Flynn James E
5 Feb 21
SC 13G
Genesys Ventures II LP
30 Apr 20
SC 13G
BDC CAPITAL INC.
10 Mar 20
SC 13G
Profound Medical Corp.
13 Feb 20
SC 13G
Beneficial ownership report
7 Feb 20